PAK2 was a necessary interaction partner of ARHGDIB, and knockdown of PAK2 greatly reduced ARHGDIB-induced cell invasion and ARHGDIB-mediated chemoresistance in gastric cancer [37], and loss of SATB1 in lung cancer has been shown as a possible marker for poor survival [38]. Here, ARHGDIB is linked to lung cancer.